Market Research Logo

BELLUS Health Inc (BLU) - Financial and Strategic SWOT Analysis Review

BELLUS Health Inc (BLU) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company’s pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second indication called sarcoidosis; AMO-01 related to Fragile X syndrome and ALZ-801 for the treatment of Alzheimer’s disease. BELLUS Health is headquartered in Laval, Quebec, Canada.

BELLUS Health Inc Key Recent Developments

May 15,2018: BELLUS Health Announces Financial Results for the First Quarter Ended March 31, 2018
Feb 21,2018: BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017
Jan 09,2018: BELLUS Health Receives Milestone Payment from Taro Pharmaceuticals
Nov 08,2017: BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017
Sep 27,2017: BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
BELLUS Health Inc - Key Facts
BELLUS Health Inc - Key Employees
BELLUS Health Inc - Key Employee Biographies
BELLUS Health Inc - Major Products and Services
BELLUS Health Inc - History
BELLUS Health Inc - Company Statement
BELLUS Health Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
BELLUS Health Inc - Business Description
BELLUS Health Inc - SWOT Analysis
SWOT Analysis - Overview
BELLUS Health Inc - Strengths
BELLUS Health Inc - Weaknesses
BELLUS Health Inc - Opportunities
BELLUS Health Inc - Threats
BELLUS Health Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
BELLUS Health Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 15, 2018: BELLUS Health Announces Financial Results for the First Quarter Ended March 31, 2018
Feb 21, 2018: BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017
Jan 09, 2018: BELLUS Health Receives Milestone Payment from Taro Pharmaceuticals
Nov 08, 2017: BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017
Sep 27, 2017: BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors
Aug 09, 2017: BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017
Feb 28, 2017: Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2016
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
BELLUS Health Inc, Key Facts
BELLUS Health Inc, Key Employees
BELLUS Health Inc, Key Employee Biographies
BELLUS Health Inc, Major Products and Services
BELLUS Health Inc, History
BELLUS Health Inc, Subsidiaries
BELLUS Health Inc, Key Competitors
BELLUS Health Inc, Ratios based on current share price
BELLUS Health Inc, Annual Ratios
BELLUS Health Inc, Annual Ratios (Cont...1)
BELLUS Health Inc, Interim Ratios
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
BELLUS Health Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
BELLUS Health Inc, Performance Chart (2013 - 2017)
BELLUS Health Inc, Ratio Charts
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
BELLUS Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report